Eledon Free Cash Flow from 2010 to 2024
| ELDN Stock | USD 4.07 0.22 5.71% |
Free Cash Flow | First Reported 2013-09-30 | Previous Quarter -7.8 M | Current Value -11.8 M | Quarterly Volatility 3.1 M |
Check Eledon Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eledon Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 494.4 K, Interest Expense of 1 M or Selling General Administrative of 10.4 M, as well as many indicators such as Price To Sales Ratio of 149, Dividend Yield of 9.0E-4 or PTB Ratio of 6.5 K. Eledon financial statements analysis is a perfect complement when working with Eledon Pharmaceuticals Valuation or Volatility modules.
Eledon | Free Cash Flow |
Latest Eledon Pharmaceuticals' Free Cash Flow Growth Pattern
Below is the plot of the Free Cash Flow of Eledon Pharmaceuticals over the last few years. It is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets. Eledon Pharmaceuticals' Free Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eledon Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Free Cash Flow | 10 Years Trend |
|
Free Cash Flow |
| Timeline |
Eledon Free Cash Flow Regression Statistics
| Arithmetic Mean | (22,221,577) | |
| Coefficient Of Variation | (54.17) | |
| Mean Deviation | 10,589,759 | |
| Median | (15,499,000) | |
| Standard Deviation | 12,038,192 | |
| Sample Variance | 144.9T | |
| Range | 32.5M | |
| R-Value | (0.57) | |
| Mean Square Error | 105.4T | |
| R-Squared | 0.32 | |
| Significance | 0.03 | |
| Slope | (1,533,288) | |
| Total Sum of Squares | 2028.9T |
Eledon Free Cash Flow History
Other Fundumenentals of Eledon Pharmaceuticals
Eledon Pharmaceuticals Free Cash Flow component correlations
About Eledon Pharmaceuticals Financial Statements
Eledon Pharmaceuticals investors utilize fundamental indicators, such as Free Cash Flow, to predict how Eledon Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Free Cash Flow | -39.5 M | -37.6 M | |
| EV To Free Cash Flow | -1.1 K | -1.1 K | |
| Price To Free Cash Flows Ratio | -1.1 K | -1.1 K | |
| Free Cash Flow Operating Cash Flow Ratio | 0.90 | 0.80 |
Pair Trading with Eledon Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eledon Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eledon Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Eledon Stock
| 0.83 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.8 | MTEM | Molecular Templates | PairCorr |
| 0.74 | ME | 23Andme Holding | PairCorr |
| 0.74 | TPST | Tempest Therapeutics | PairCorr |
| 0.72 | NKTX | Nkarta Inc | PairCorr |
The ability to find closely correlated positions to Eledon Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eledon Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eledon Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eledon Pharmaceuticals to buy it.
The correlation of Eledon Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eledon Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eledon Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eledon Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Eledon Pharmaceuticals Correlation against competitors. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.73 | Return On Assets (0.33) | Return On Equity (0.25) |
The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.